Skip to main content

Table 2 Treatment plans and outcomes of the 72 cases of small cell cervical carcinoma

From: Analysis of the impact of platinum-based combination chemotherapy in small cell cervical carcinoma: a multicenter retrospective study in Chinese patients

Case Age FIGO stage Treatment Response to CT Outcome (months)
    Surgery PMCT PMRT   
1 29 Ia Yes EP ×4 No CR NED (98 M)
2 52 IIa Yes / Yes / DOD (8 M)
3 27 Ib2 Yes TP ×4 Yes CR NED (42 M)
4 58 Ib1 Yes VAC ×4 Yes PR NED (23 M)
5 42 Ib2 Yes VAC ×1 + EP ×6 No PROG DOD (17 M)
6 39 Ib2 Yes CBP ×2 + TP ×4 No SD DOD (28 M)
7 54 IIIb Yes P ×1 No PROG DOD (25 M)
8 43 Ib1 Yes / No / NED (119 M)
9 36 Ib1 Yes CAP ×2 No PROG DOD (22 M)
10 47 Ib1 Yes CBP ×4 Yes CR NED (70 M)
11 46 Ib2 Yes ITP ×4 Yes SD DOD (34 M)
12 38 IIa Yes CBP ×4 Yes SD DOD (38 M)
13 58 IIa Yes / No / DOD (6 M)
14 48 IIb Yes / Yes / DOD (2 M)
15 24 Ib2 Yes IP ×1 Yes PROG DOD (5 M)
16 51 Ib1 Yes VAC ×2 + EP ×2 No PROG DOD (23 M)
17 65 IIa Yes VAC ×2 + EP ×1 Yes PROG DOD (23 M)
18 37 IIb No / Yes / DOD (6 M)
19 42 IIa Yes VAC ×2 + EP ×2 Yes PR DOD (33 M)
20 51 Ib2 Yes EP ×4 No CR NED (43 M)
21 36 Ib1 Yes TP ×4 Yes PR DOD (11 M)
22 48 Ib2 Yes VAC ×2 + EP ×2 No PR NED (32 M)
23 55 Ib1 Yes (IP + CP) ×5 No PROG DOD (28 M)
24 41 Ib1 Yes EP ×3 No PR NED (20 M)
25 32 IIb No / Yes / NED (63 M)
26 40 IIIb Yes TP ×5 Yes PR NED (64 M)
27 44 Ib1 Yes EP ×4 / CR NED (59 M)
28 34 Ib1 No VAC ×2 + EP ×2 No PR NED (22 M)
29 62 IIb Yes / / / NED (20 M)
30 41 Ib2 Yes EP ×4 Yes CR NED (17 M)
31 56 Ib1 Yes EP ×4 Yes CR NED (46 M)
32 66 IIa Yes EP ×4 No CR NED (12 M)
33 39 IIb No / Yes / DOD (12 M)
34 38 Ib1 Yes EP ×4 Yes SD DOD (18 M)
35 54 Ib1 Yes EP ×4 No PR NED (15 M)
36 39 Ib1 Yes EP ×4 Yes PR NED (13 M)
37 38 Ib1 Yes EP ×4 No CR NED (24 M)
38 51 IIa Yes EP ×4 No CR NED (25 M)
39 47 Ib1 Yes EP ×4 Yes PR NED (26 M)
40 28 IV No / / / DOD (1 M)
41 40 Ib2 No / / / NED (8 M)
42 48 Ib1 Yes EP ×4 No CR NED (21 M)
43 57 IIa Yes EP ×4 Yes CR NED (11 M)
44 29 Ib2 Yes / No CR NED (29 M)
45 38 IIa Yes EP ×4 Yes SD DOD (18 M)
46 59 Ib1 Yes EP ×4 No / NED (16 M)
47 61 Ib1 Yes EP ×4 No CR NED (24 M)
48 43 Ib2 Yes EP ×4 Yes CR NED (28 M)
49 40 Ib1 Yes EP ×4 No CR NED (13 M)
50 42 Ib1 Yes VAC ×4 No CR NED (74 M)
51 45 Ib1 Yes / No / DOD (19 M)
52 52 Ib2 Yes EP ×4 No CR NED (46 M)
53 26 Ib1 Yes EP ×4 / CR NED (32 M)
54 31 IIb No EP ×4 + VAC ×2 Yes PR DOD (17 M)
55 55 Ib1 Yes EP ×4 No CR NED (50 M)
56 50 Ib1 Yes EP ×5 Yes PR DOD (29 M)
57 44 Ib2 Yes EP ×4 No CR DOD (33 M)
58 54 Ib1 Yes / Yes / DOD (38 M)
59 43 IIa Yes / Yes / DOD (15 M)
60 40 Ib2 Yes TP ×4 No PR DOD (34 M)
61 36 IIa Yes / Yes / DOD (14 M)
62 46 Ib1 Yes EP ×4 No PR DOD (49 M)
63 48 IIb Yes EP ×4 Yes PR DOD (20 M)
64 31 Ib1 Yes EP ×4 / CR NED (10 M)
65 33 IIb No VAC ×2 + EP ×6 Yes PROG DOD (11 M)
66 67 IIa Yes EP ×4 Yes CR NED (18 M)
67 53 IIb No / Yes / DOD (6 M)
68 38 IIa Yes EP ×4 + VAC ×2 Yes PR DOD (34 M)
69 42 Ia Yes EP ×4 No PR NED (32 M)
70 66 IIb Yes / No / DOD (5 M)
71 45 Ib2 Yes EP ×4 Yes CR NED (15 M)
72 41 Ib1 Yes EP ×4 Yes CR NED (13 M)
  1. PMCT, postoperative chemotherapy; PMRT, postoperative radiotherapy; CT, chemotherapy; EP, etoposide + cisplatin; VAC, vincristine + doxorubicin + cyclophosphamide; TP, paclitaxel + cisplatin; CBP, cyclophosphamide + bleomycin + carboplatin/cisplatin; CBP, cyclophosphamide + adriamycin + carboplatin/cisplatin; ITP, ifosfamide + pirarubicin + cisplatin; CR, complete response; PR, partial response; SD, stable disease; PROG, progressive disease; M, months; DOD, died of disease; NED, no evidence of disease.